Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MYL12A and MYL12B antisense RNA 1 (MYL12-AS1)
- Target
- MYL12-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other (noncoding RNA)
01
Overview
MYL12-AS1 is a long non-coding antisense RNA transcribed from the MYL12A and MYL12B gene locus. Like other lncRNA antisense transcripts, it is involved in complex regulation of gene expression, potentially affecting transcription, translation, and chromatin state. Antisense RNAs are important regulators in both physiological and pathological contexts, including cancer, imprinting, and development. They can act by affecting transcription either in cis (locally at their site of synthesis) or in trans (distantly within the nucleus), and their mechanisms include transcriptional interference via promoter competition, occlusion, and chromatin remodeling. Although MYL12-AS1 has not been established as a direct drug target or biomarker, the broader class of antisense lncRNAs is attracting growing attention in basic RNA biology and precision medicine research.
- Other names
- MYL12-AS1
02
Mechanism of action
Not applicable (no known drugs directly target MYL12-AS1)
03
Biological functions
Regulation of gene expression (especially the MYL12A and MYL12B genes)Epigenetic regulationPossible roles in transcriptional interferenceCell cycle and cell proliferation modulation (by analogy to other antisense RNAs)
04
Disease associations
Potential role in cancer (dysregulation of antisense RNAs has been implicated in tumorigenesis and epigenetic silencing of tumor suppressors)Other (potential implications in disease via regulation of chromatin and imprinting)
Beyond the preview
Go deeper on MYL12A and MYL12B antisense RNA 1 (MYL12-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYL12A and MYL12B antisense RNA 1 (MYL12-AS1).